Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of intravenous bimagrumab in sporadic inclusion body myositis
jRCT2080223024Phase 3
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of bimagrumab in sporadic inclusion body myositis (sIBM) (5 arms), sponsored by Novartis.
02
Drugs
bimagrumab
03
Conditions
sporadic inclusion body myositis (sIBM)
Beyond the preview
Go deeper on jRCT2080223024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223024.